Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Gemcitabine + Nab-paclitaxel + PF-04136309|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Gemcitabine||Gemzar||Difluorodeoxycytidine Hydrochlorothiazide|LY-188011||Chemotherapy - Antimetabolite 13||Gemzar (gemcitabine) is converted in cells to difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP), which act to inhibit ribonucleoside reductase and as a deoxynucleotide analog respectively, resulting in DNA strand termination and apoptosis (NCI Drug Dictionary).|
|Nab-paclitaxel||Abraxane||ABI-007|Paclitaxel Protein-bound||Chemotherapy - Taxane 2||Abraxane (nab-paclitaxel) is an albumin-stablized version of paclitaxel, which binds microtubules and prevents depolymerization, resulting in decreased cell motility and division (NCI Drug Dictionary).|
|PF-04136309||PF-04136309 is a CCR2 antagonist that inhibits CCR2 signaling, resulting in inhibition of tumor progression (PMID: 27055731, PMID: 31297636).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||pancreatic ductal adenocarcinoma||no benefit||Gemcitabine + Nab-paclitaxel + PF-04136309||Phase I||Actionable||In a Phase Ib trial, PF-04136309 in combination with Abraxane (nab-paclitaxel) and Gemzar (gemcitabine) resulted in a high incidence of pulmonary toxicity (24%, 5/21) in patients with pancreatic ductal adenocarcinoma, and resulted in an objective response rate of 23.8% (5/21, all partial responses), which did not demonstrate improvement compared to the efficacy of Abraxane (nab-paclitaxel) plus Gemzar (gemcitabine) established in prior studies (PMID: 31297636; NCT02732938).||31297636|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02732938||Phase I||Gemcitabine + Nab-paclitaxel + PF-04136309||Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients (CCR2i)||Terminated||USA||0|